Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
a16z invests, Biogen CEO oversees! Cardiovascular new drug developer Braveheart (BRVE.US) sprints for Nasdaq IPO

a16z invests, Biogen CEO oversees! Cardiovascular new drug developer Braveheart (BRVE.US) sprints for Nasdaq IPO

智通财经智通财经2026/07/16 14:01
Show original
By:智通财经
Braveheart Bio Inc., a clinical-stage biopharmaceutical company backed by A16z, submitted its IPO application to Nasdaq on Wednesday, according to Zhitong Finance APP.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Consulting giant Bain sounds the alarm: The global AI industry needs to achieve $6 trillion in annual revenue to sustain the “cash burn” of data centers

Bain stated that by 2031, the global artificial intelligence (AI) industry needs to achieve annual revenue of $6 trillion in order to justify the massive capital investment currently being made in building data centers worldwide.

智通财经•2026/09/29 04:21

Samsung Electronics' 2nm yield approaches 60%, aiming at TSMC to compete for tech giants' orders

The yield rate of Samsung Electronics' foundry division's 2nm process has increased to nearly 60%, a significant improvement from around 30% in mid-2023. After stabilizing the yield, Samsung has shifted its engineering focus to power consumption and heat dissipation optimization, and is accelerating the development of the more powerful second-generation process, SF2P, aiming for mass production within the year. Strategically, Samsung plans to supply 2nm chips to Tesla next year, using this as a stepping stone to enter the large-scale tech client market.

华尔街见闻•2026/09/29 04:01